RBMY1E

Across TCGA pan-cancer cohorts, RBMY1E RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RBMY1E data layer compared with 1 for mutation status.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RBMY1E RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RBMY1E expression acts as an unfavorable survival marker.

BRCA, LUAD, and GBM are the cancer types where RBMY1E RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Tertile	All	0.337	0.925	<.001	126	view →
LUAD	OS	Tertile	III,IV	0.057	0.680	<.001	99	view →
GBM	OS	Tertile	All	0.030	0.416	<.001	36	view →
THCA	OS	Tertile	All	0.188	0.942	<.001	36	view →
LUSC	OS	Tertile	III,IV	0.145	0.690	.001	36	view →
PCPG	OS	Tertile	All	0.021	0.962	<.001	36	view →
LGG	OS	Tertile	All	0.393	0.812	.033	18	view →
LIHC	DFS	Tertile	All	0.444	0.580	.026	12	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RBMY1E–BRCA (OS)

Open the BRCA breakdown →